Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Status: Enrolling
Updated:  9/5/2012
Clinical Research Facility
mi
from
Seattle, WA
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Status: Enrolling
Updated: 9/5/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Status: Enrolling
Updated:  9/5/2012
Clinical Research Facility
mi
from
Milwaukee, WI
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Status: Enrolling
Updated: 9/5/2012
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors
Status: Enrolling
Updated:  9/6/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors
Status: Enrolling
Updated: 9/6/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors
Status: Enrolling
Updated:  9/6/2012
Pfizer Investigational Site
mi
from
Arvada, CO
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors
Status: Enrolling
Updated: 9/6/2012
Pfizer Investigational Site
mi
from
Arvada, CO
Click here to add this to my saved trials
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors
Status: Enrolling
Updated:  9/6/2012
Pfizer Investigational Site
mi
from
Boston, MA
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors
Status: Enrolling
Updated: 9/6/2012
Pfizer Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Boston, MA
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Augusta, GA
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Detroit, MI
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated:  9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated: 9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
California Cancer Associates
mi
from
Fresno, CA
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
California Cancer Associates
mi
from
Fresno, CA
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
Wilshire Oncology Medical Group
mi
from
Corona, CA
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
Wilshire Oncology Medical Group
mi
from
Corona, CA
Click here to add this to my saved trials
Lung Cancer Location: a Repository
Lung Cancer Location: A Prospective Repository
Status: Enrolling
Updated:  9/11/2012
Clarian/IUPUI: University Hospital
mi
from
Indianapolis, IN
Lung Cancer Location: a Repository
Lung Cancer Location: A Prospective Repository
Status: Enrolling
Updated: 9/11/2012
Clarian/IUPUI: University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  9/11/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 9/11/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Status: Enrolling
Updated:  9/11/2012
Progenics Pharmaceuticals, Inc.
mi
from
Tarrytown, NY
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Status: Enrolling
Updated: 9/11/2012
Progenics Pharmaceuticals, Inc.
mi
from
Tarrytown, NY
Click here to add this to my saved trials
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Status: Enrolling
Updated:  9/12/2012
Broadway Family Medicine Clinic
mi
from
Minneapolis, MN
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Status: Enrolling
Updated: 9/12/2012
Broadway Family Medicine Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
GRN1005 for Brain Metastases From Breast or Lung Cancer
A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/13/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
GRN1005 for Brain Metastases From Breast or Lung Cancer
A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/13/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
Dartmouth-Hitchcock Medical Center - Lebanon
mi
from
Lebanon, NH
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
Dartmouth-Hitchcock Medical Center - Lebanon
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
Dartmouth-Hitchcock Clinic - Manchester
mi
from
Manchester, NH
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
Dartmouth-Hitchcock Clinic - Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
St. Joseph Hospital
mi
from
Nashua, NH
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
St. Joseph Hospital
mi
from
Nashua, NH
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
Providence VA Medical Center
mi
from
Providence, RI
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
Providence VA Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
Mountainview Medical
mi
from
Berlin, VT
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
Dartmouth-Hitchcock Medical Center - St. Johnsbury
mi
from
St. Johnsbury, VT
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
Dartmouth-Hitchcock Medical Center - St. Johnsbury
mi
from
St. Johnsbury, VT
Click here to add this to my saved trials
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated:  9/17/2012
Veteran's Administration Hospital
mi
from
White River Junction, VT
Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Status: Enrolling
Updated: 9/17/2012
Veteran's Administration Hospital
mi
from
White River Junction, VT
Click here to add this to my saved trials
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Encino, CA
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The Role of Meat-borne Carcinogens in Pancreatic Cancer
Understanding the Role of Meat-Borne Carcinogen in Pancreatic Cancer Etiology
Status: Enrolling
Updated:  9/18/2012
Univ of Minnesota
mi
from
Minneapolis, MN
The Role of Meat-borne Carcinogens in Pancreatic Cancer
Understanding the Role of Meat-Borne Carcinogen in Pancreatic Cancer Etiology
Status: Enrolling
Updated: 9/18/2012
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Assessment of Patient Experience During Treatment for Cancer
Assessment of Patient Experience During Treatment for Cancer
Status: Enrolling
Updated:  9/18/2012
Stanford University Cancer Institute
mi
from
Stanford, CA
Assessment of Patient Experience During Treatment for Cancer
Assessment of Patient Experience During Treatment for Cancer
Status: Enrolling
Updated: 9/18/2012
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors
Status: Enrolling
Updated:  9/20/2012
GSK Investigational Site
mi
from
Glendale, AZ
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors
Status: Enrolling
Updated: 9/20/2012
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors
Status: Enrolling
Updated:  9/20/2012
GSK Investigational Site
mi
from
Knoxville, TN
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors
Status: Enrolling
Updated: 9/20/2012
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  9/20/2012
Clinical Research Facility
mi
from
Encino, CA
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 9/20/2012
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  9/20/2012
Clinical Research Facility
mi
from
Aurora, CO
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 9/20/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  9/20/2012
Clinical Research Facility
mi
from
Tampa, FL
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 9/20/2012
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  9/20/2012
Clinical Research Facility
mi
from
Memphis, TN
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 9/20/2012
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Banner Healthcare
mi
from
Gilbert, AZ
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Banner Healthcare
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Christiana Care Health Services Helen Graham Cancer Center
mi
from
Newark, DE
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Christiana Care Health Services Helen Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Jackson North Medical Center
mi
from
Miami, FL
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Jackson North Medical Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Sylvester Comprehensive Cancer Center Univ. Miami
mi
from
Miami, FL
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Sylvester Comprehensive Cancer Center Univ. Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Moffitt Cancer Center
mi
from
Tampa, FL
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Winship Cancer Institute
mi
from
Atlanta, GA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Mountain States Tumor Institute
mi
from
Boise City, ID
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Mountain States Tumor Institute
mi
from
Boise City, ID
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Goshen Center for Cancer Care
mi
from
Goshen, IN
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Goshen Center for Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Detroit Clinical Research Center
mi
from
Novi, MI
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Detroit Clinical Research Center
mi
from
Novi, MI
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
St. Mary's Trinity Healthcare
mi
from
Grand Rapids, MI
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
St. Mary's Trinity Healthcare
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
Click here to add this to my saved trials